Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Assets (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Assets for 7 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 5.72% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 5.72% year-over-year, with the annual reading at $1.1 billion for FY2025, 5.72% up from the prior year.
  • Assets hit $1.1 billion in Q4 2025 for Immunocore Holdings, down from $1.1 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.1 billion in Q3 2025 to a low of $406.8 million in Q4 2021.
  • Historically, Assets has averaged $900.6 million across 5 years, with a median of $1.0 billion in 2024.
  • Biggest five-year swings in Assets: soared 69.1% in 2024 and later rose 1.65% in 2025.
  • Year by year, Assets stood at $406.8 million in 2021, then grew by 25.58% to $510.8 million in 2022, then increased by 16.87% to $597.0 million in 2023, then skyrocketed by 69.1% to $1.0 billion in 2024, then increased by 5.72% to $1.1 billion in 2025.
  • Business Quant data shows Assets for IMCR at $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.